Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
grade C 7.59 -8.66% -0.72
NERV closed down 8.66 percent on Friday, March 22, 2019, on 1.19 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical NERV trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Mar 22 Below Lower BB Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -8.66%
Mar 21 Bollinger Band Squeeze Range Contraction -8.66%
Mar 21 Upper Bollinger Band Walk Strength -8.66%

Older signals for NERV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Drugs Schizophrenia Parkinson's Disease Psychoactive Drugs Neurochemistry Ketones Major Depressive Disorder Treatment Of Parkinson's Disease Antidepressants Central Nervous System Diseases Treatment Of Major Depressive Disorder Treatment Of Central Nervous System Diseases
Is NERV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.95
52 Week Low 5.8
Average Volume 134,222
200-Day Moving Average 8.7073
50-Day Moving Average 7.5318
20-Day Moving Average 8.135
10-Day Moving Average 8.191
Average True Range 0.3913
ADX 24.11
+DI 22.7313
-DI 23.7901
Chandelier Exit (Long, 3 ATRs ) 7.536100000000001
Chandelier Exit (Short, 3 ATRs ) 8.7339
Upper Bollinger Band 8.619
Lower Bollinger Band 7.651
Percent B (%b) -0.06
BandWidth 11.899201
MACD Line 0.1625
MACD Signal Line 0.216
MACD Histogram -0.0535
Fundamentals Value
Market Cap 322.65 Million
Num Shares 42.5 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -7.03
Price-to-Sales 0.00
Price-to-Book 2.36
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.67
Resistance 3 (R3) 8.78 8.54 8.49
Resistance 2 (R2) 8.54 8.26 8.48 8.43
Resistance 1 (R1) 8.06 8.09 7.94 7.95 8.37
Pivot Point 7.82 7.82 7.76 7.76 7.82
Support 1 (S1) 7.34 7.54 7.22 7.23 6.81
Support 2 (S2) 7.10 7.37 7.04 6.75
Support 3 (S3) 6.62 7.10 6.69
Support 4 (S4) 6.51